Have a personal or library account? Click to login
Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study Cover

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

Forum of Clinical Oncology
Volume 6 (2015): Issue 4 (December 2015)
By: Hend Ahmed El-Hadaad,  Hanan Ahmed Wahba and  Hayam Fathy Abd-El Hay Ghazy  
Open Access
|Mar 2016

References

  1. [1] Curti B, Jana BR, Javeed M, Makhoul I, Sachdeva K, Hu W et al. Harris, JE, ed. “Renal Cell Carcinoma”. Medscape Reference. WebMD. Retrieved 7 March 2014
    Search in Google Scholar
  2. [2] Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of renal cell carcinoma. World Journal of Urology. 2005; 23:202-12.10.1007/s00345-004-0466-015812574
    Search in Google Scholar
  3. [3] McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23:133-41.10.1200/JCO.2005.03.20615625368
    Search in Google Scholar
  4. [4] Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell carcinoma. .J Clin Oncol. 2003; 21:3127-32.10.1200/JCO.2003.02.122227532712915604
    Search in Google Scholar
  5. [5] Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R et al. Medroxyprogestrone, interferon alfa-2a, interleukin-2 or combination of both cytokines in patients with metastatic renal cell carcinoma. Cancer. 2007; 110:2468-77.10.1002/cncr.2305617932908
    Search in Google Scholar
  6. [6] Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 2:CD001425.10.1002/14651858.CD001425.pub215674877
    Search in Google Scholar
  7. [7] Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6: 1:S55-S57.
    Search in Google Scholar
  8. [8] Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18:2972-80.10.1200/JCO.2000.18.16.297210944130
    Search in Google Scholar
  9. [9] Negrier S1, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998; 338:1272-8.10.1056/NEJM1998043033818059562581
    Search in Google Scholar
  10. [10] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear cell renal carcinoma. N Engl J Med. 2007; 365:125-34.10.1056/NEJMoa06065517215530
    Search in Google Scholar
  11. [11] Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014; 110:1125-32.10.1038/bjc.2013.832395086124434434
    Search in Google Scholar
  12. [12] Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013; 49:1287-96.10.1016/j.ejca.2012.12.01023321547
    Search in Google Scholar
  13. [13] Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomized phase 3 trial. Lancet. 2011; 378:1931-39.10.1016/S0140-6736(11)61613-9
    Search in Google Scholar
  14. [14] Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2:471-8.
    Search in Google Scholar
  15. [15] Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9:327-37.
    Search in Google Scholar
  16. [16] Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003; 9:4641-52.
    Search in Google Scholar
  17. [17] Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:16-24.10.1200/JCO.2005.02.2574
    Search in Google Scholar
  18. [18] Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295:2516-24.10.1001/jama.295.21.2516
    Search in Google Scholar
  19. [19] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.10.1093/jnci/92.3.205
    Search in Google Scholar
  20. [20] Trotti A1, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al. CTCAE v.3.0: development of a comprehensive grading system for adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13:176-81.10.1016/S1053-4296(03)00031-6
    Search in Google Scholar
  21. [21] Escudier B, Szczlik C, Eisen T, Stadler WM, Schwartz B, Shan M et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005; 24:380s abstract.10.1200/jco.2005.23.16_suppl.lba4510
    Search in Google Scholar
  22. [22] Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163:408-17.10.1016/S0022-5347(05)67889-5
    Search in Google Scholar
  23. [23] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27:3584-90.10.1200/JCO.2008.20.1293364630719487381
    Search in Google Scholar
  24. [24] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007; 356:115-24.10.1056/NEJMoa06504417215529
    Search in Google Scholar
  25. [25] Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013; 5:338-53.10.1177/1756287213505672382511224294292
    Search in Google Scholar
  26. [26] Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther. 2012; 12:1571-7.10.1586/era.12.8123181412
    Search in Google Scholar
  27. [27] Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low risk clear renal cell carcinoma. Cancer. 2014 120:1059-67.10.1002/cncr.28521407502924382589
    Search in Google Scholar
  28. [28] Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013; 45:849-50.10.1038/ng.270823892664
    Search in Google Scholar
  29. [29] Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013; 369:722-31.10.1056/NEJMoa130398923964934
    Search in Google Scholar
  30. [30] Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al. Clinical factors associated with outcome in patients with metastatic clear cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110:543-50.10.1002/cncr.2282717577222
    Search in Google Scholar
  31. [31] Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ et al. Randomised phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012; 30:1371-7.10.1200/JCO.2011.36.413322430274
    Search in Google Scholar
  32. [32] Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012; 15:1139-48.10.3111/13696998.2012.70868922808923
    Search in Google Scholar
  33. [33] Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011; 29:977-88.10.2165/11593370-000000000-0000021854079
    Search in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0017 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 23 - 27
Submitted on: Aug 30, 2015
|
Accepted on: Dec 15, 2015
|
Published on: Mar 31, 2016
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Sunitinib,
Metastasis,
Renal Cell Carcinoma,
Targeted agents
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2016 Hend Ahmed El-Hadaad, Hanan Ahmed Wahba, Hayam Fathy Abd-El Hay Ghazy, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 6 (2015): Issue 4 (December 2015)Next article